The present invention relates to uses of Macrolactin A produced by
Bacillus polyfermenticus KJS-2 (KCCM 10769P), which is a new bacillus
strain, as an antibiotic. Macrolactin A of the present invention, which
is produced by Bacillus polyfermenticus KJS-2, shows a broad spectrum of
antibiotic activity against a variety of microorganisms and fungi, and is
proved to be very efficient for the inhibition of particularly
vancomycin-resistant enterococci (VRE) and methicillin-resistant
Staphylococcus Aureus (MRSA) that are multidrug-resistant bacteria. The
antibiotic Macrolactin A produced by Bacillus polyfermenticus KJS-2, can
be used as an excellent antibiotic against vancomycin-resistant
enterococci (VRE) and methicillin-resistant Staphylococcus Aureus (MRSA),
and thus the present invention is a very useful invention for medical
industry.